Bionaturis Group has received notification from the patent office of Israel of the approval of the patent entitled “Split inteins and uses thereof”, contributing to the protection of the Splittera system, joining to the already granted in the main European markets, China, Japan, and Australia.


This patent family is of special relevance for Bionaturis group since Splittera is subject of a worldwide exclusive licensing agreement with a top leading multinational company, for its commercialization in the industrial purification of biological products. The agreement contemplates upfront, milestone-payments and royalties for sales. This agreement is a proof of principle of the usefulness and added value of Splittera for the biopharmaceutical sector, which presents a global expected market figure worth of 236 billion dollars by 2019.

Splittera is part of the technological portfolio of the CDMO division of the biotechnological group, provided by ZIP Solutions, a specialist in bioprocesses at industrial scale.
Please, click here to read the Relevant Information (only in Spanish)